Health state utilities associated with attributes of treatments for hepatitis C

Louis S. Matza (Lead / Corresponding author), Sandhya J. Sapra, John F. Dillon, Anupama Kalsekar, Evan W. Davies, Mary K. Devine, Jessica B. Jordan, Amanda S. Landrian, David H. Feeny

    Research output: Contribution to journalArticlepeer-review

    36 Citations (Scopus)
    217 Downloads (Pure)


    Background: Cost-utility analyses are frequently conducted to compare treatments for hepatitis C, which are often associated with complex regimens and serious adverse events. Thus, the purpose of this study was to estimate the utility associated with treatment administration and adverse events of hepatitis C treatments. Design: Health states were drafted based on literature review and clinician interviews. General population participants in the UK valued the health states in time trade-off (TTO) interviews with 10- and 1-year time horizons. The 14 health states described hepatitis C with variations in treatment regimen and adverse events. Results: A total of 182 participants completed interviews (50 % female; mean age = 39.3 years). Utilities for health states describing treatment regimens without injections ranged from 0.80 (1 tablet) to 0.79 (7 tablets). Utilities for health states describing oral plus injectable regimens were 0.77 (7 tablets), 0.75 (12 tablets), and 0.71 (18 tablets). Addition of a weekly injection had a disutility of −0.02. A requirement to take medication with fatty food had a disutility of −0.04. Adverse events were associated with substantial disutilities: mild anemia, −0.12; severe anemia, −0.32; flu-like symptoms, −0.21; mild rash, −0.13; severe rash, −0.48; depression, −0.47. One-year TTO scores were similar to these 10-year values. Conclusions: Adverse events and greater treatment regimen complexity were associated with lower utility scores, suggesting a perceived decrease in quality of life beyond the impact of hepatitis C. The resulting utilities may be used in models estimating and comparing the value of treatments for hepatitis C.

    Original languageEnglish
    Pages (from-to)1005-1018
    Number of pages14
    JournalEuropean Journal of Health Economics
    Issue number9
    Early online date7 Dec 2014
    Publication statusPublished - 1 Dec 2015


    • Cost-utility
    • Hepatitis C
    • Time horizon
    • Time trade-off
    • Treatment process utility
    • Utility

    ASJC Scopus subject areas

    • Health Policy
    • Economics, Econometrics and Finance (miscellaneous)


    Dive into the research topics of 'Health state utilities associated with attributes of treatments for hepatitis C'. Together they form a unique fingerprint.

    Cite this